Drugs / SLGN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05045261 | Feb 2022 → Jun 2024 | chronic hepatitis B virus infection | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLGN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05045261 ↗ |
| Action | Activate | “a TLR8 agonist (SLGN) treatment” NCT05045261 ↗ |
| Target | TLR8 | “a TLR8 agonist (SLGN) treatment” NCT05045261 ↗ |